- Corporate Officers - N
- Nussbaum Ran
Insider Trading History of Nussbaum Ran
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Nussbaum Ran since 2015.
This trader's CIK number is 1609805.
At the time of last reporting, Nussbaum Ran was the Director of Urogen Pharma Ltd.. (stock ticker symbol URGN).
Also see all insider trading activities at Urogen Pharma Ltd..
Note that in the past
Nussbaum Ran also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Eloxx Pharmaceuticals, Inc. (ELOX) by Nussbaum Ran
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2019 | ELOX | 200,000 | $1,800,000 | 0 | $0 | 0 | $0 |
| 2018 | ELOX | 362,600 | $3,510,330 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Arqule Inc (ARQL) by Nussbaum Ran
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2019 | ARQL | 307,692 | $2,999,997 | 0 | $0 | 1,669,714 | $2,921,999 |
| 2018 | ARQL | 190,429 | $1,028,329 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Urogen Pharma Ltd. (URGN) by Nussbaum Ran
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2022 | URGN | 0 | $0 | 0 | $0 | 2,211 | $11,055 |
| 2022 | URGN | 0 | $0 | 0 | $0 | 1,030 | $5,150 |
Yearly summary of insider trading at Kite Pharma, Inc. (KITE) by Nussbaum Ran
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2017 | KITE | 9,832 | $679,519 | 0 | $0 | 0 | $0 |
| 2015 | KITE | 0 | $0 | 499,164 | $28,765,180 | 0 | $0 |
Yearly summary of insider trading at Keros Therapeutics, Inc. (KROS) by Nussbaum Ran
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2020 | KROS | 437,499 | $6,999,984 | 0 | $0 | 0 | $0 |
Insider trading activities at 5 companies by Nussbaum Ran:
1. Eloxx Pharmaceuticals, Inc. (ELOX)
2. Arqule Inc (ARQL)
3. Urogen Pharma Ltd. (URGN)
4. Kite Pharma, Inc. (KITE)
5. Keros Therapeutics, Inc. (KROS)
Table 1. Insider trading of Eloxx Pharmaceuticals, Inc. (ELOX) by Nussbaum Ran
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2019-06-24 | ELOX | Buy | 200,000 | 9.00 | 1,800,000 |
| 2018-04-30 | ELOX | Buy | 350,000 | 9.75 | 3,412,500 |
| 2018-03-22 | ELOX | Buy | 6,000 | 8.00 | 48,000 |
| 2018-03-21 | ELOX | Buy | 6,600 | 7.55 | 49,830 |
Table 2. Insider trading of Arqule Inc (ARQL) by Nussbaum Ran
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2019-12-24 | ARQL | Option Ex | 1,669,714 | 1.75 | 2,921,999 |
| 2019-06-27 | ARQL | Buy | 307,692 | 9.75 | 2,999,997 |
| 2018-07-13 | ARQL | Buy | 181,818 | 5.50 | 999,999 |
| 2018-05-18 | ARQL | Buy | 8,611 | 3.29 | 28,330 |
Table 3. Insider trading of Urogen Pharma Ltd. (URGN) by Nussbaum Ran
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2022-06-16 | URGN | Option Ex | 2,211 | 5.00 | 11,055 |
| 2022-06-06 | URGN | Option Ex | 1,030 | 5.00 | 5,150 |
Table 4. Insider trading of Kite Pharma, Inc. (KITE) by Nussbaum Ran
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2017-05-09 | KITE | Buy | 9,832 | 69.11 | 679,519 |
| 2015-06-01 | KITE | Sale | 80,760 | 56.29 | 4,545,980 |
| 2015-06-02 | KITE | Sale | 224,674 | 55.67 | 12,508,724 |
| 2015-03-27 | KITE | Sale | 77,873 | 61.24 | 4,769,020 |
| 2015-03-30 | KITE | Sale | 115,857 | 59.91 | 6,941,456 |
Table 5. Insider trading of Keros Therapeutics, Inc. (KROS) by Nussbaum Ran
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2020-04-13 | KROS | Buy | 437,499 | 16.00 | 6,999,984 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Nussbaum Ran
(Director of Urogen Pharma Ltd. at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.